Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. Here, we identify a hepatocellular carcinoma (HCC) subgroup exhibiting cyclin activation through various mechanisms including hepatitis B virus (HBV) and adeno-associated virus type 2 (AAV2) insertions, enhancer hijacking and recurrent CCNA2 fusions. Cyclin A2 or E1 alterations define a homogenous entity of aggressive HCC, mostly developed in non-cirrhotic patients, characterized by a transcriptional activation of E2F and ATR pathways and a high frequency of RB1 and PTEN inactivation. Cyclin-driven HCC display a unique signature of structural rearrangements with hundreds of tandem duplications and templated insertions frequently activating TERT promoter. These rearrangements, strongly enriched in early-replicated active chromatin regions, are consistent with a break-induced replication mechanism. Pan-cancer analysis reveals a similar signature in BRCA1-mutated breast and ovarian cancers. Together, this analysis reveals a new poor prognosis HCC entity and a rearrangement signature related to replication stress.


Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Only 30% of cases are diagnosed at an early stage and are amenable to curative treatment by tumor resection or liver transplantation1. The multikinase inhibitors sorafenib2 and regorafenib3 are currently the only drugs approved for advanced HCC cases, but the median life expectancy of patients with HCC on sorafenib is only 1 year. All phase III clinical trials involving targeted molecular therapies have failed so far for various reasons including liver toxicity, lack of antitumoral potency, and the molecular heterogeneity of the disease4. Identifying homogeneous HCC subgroups sharing similar driving mechanisms and vulnerabilities is thus crucial to design successful patient-tailored clinical trials.

Most HCC develop in a cirrhotic liver, associated with various etiologies including hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol abuse, metabolic disease, and exposure to carcinogenic compounds like aflatoxin B15. The natural history of HCC in cirrhosis follows a well-established sequence with the successive development of dysplastic nodules that can transform into early stage and advanced HCC. TERT promoter mutations are the initial oncogenic events already detected in dysplastic nodules6 whereas alterations in other HCC drivers7,8,9,10,11 involved in cell cycle control (TP53, RB1, CCND1, CDKN2A), Wnt/ß-catenin signaling (CTNNB1, AXIN1), oxidative stress response (NFE2L2, KEAP1) epigenetic regulation (ARID1A, ARID2) and the AKT/mTOR and MAP kinase pathway (RPS6KA3, TSC1, TSC2, PTEN) only occur in progressed HCC12.

In 20% of the cases, HCC develops in absence of cirrhosis. These patients usually maintain adequate liver functions and, being less subject to liver toxicity, may be eligible for more treatment options. The etiology of HCC in absence of cirrhosis is largely unknown, but one mechanism of transformation involves insertional mutagenesis by the HBV virus. The first oncogenic HBV insertion was identified in cyclin A2 gene (CCNA2)13. Since then, recurrent HBV insertions were mapped in several oncogenes including CCNE1, KMT2B and TERT14,15. Recently, we identified adeno-associated virus type 2 (AAV2) insertions as a new etiology for HCC developed in absence of cirrhosis, with recurrent insertions in CCNA2 and CCNE1 genes16. However, the molecular consequences of viral insertions in cyclin genes and their precise role in HCC development remain poorly understood.

Here, we report the systematic screening of CCNA2 and CCNE1 alterations in 751 HCC. We identify new mechanisms of cyclin A2/E1 activation, and we explore the clinical and molecular characteristics of this tumor subgroup.


Viral insertions and gene fusions activate cyclin A2

To identify the exhaustive landscape of CCNA2 and CCNE1 alterations in HCC, we analyzed 751 HCC comprising an in-house series of 160 tumors (LICA-FR) analyzed by RNA sequencing (RNAseq, n = 160), whole exome (WES, n = 156) and whole genome sequencing (WGS, n = 45) (Supplementary Data 1), the TCGA17 series (334 HCC with RNA-seq and WES, 48 or which also analyzed by WGS) and the ICGC-JP11 series (257 HCC with WGS data, Supplementary Data 2).

We first screened the LICA-FR series of 160 tumors to characterize the exhaustive mechanisms activating CCNA2 and CCNE1 in HCC. We identified one HBV and 5 AAV2 insertions (four previously described in the ref. 16) in CCNA2 gene (Supplementary Data 3), all but one located within CCNA2 intron 2 (Fig. 1a). Viral insertions were associated with CCNA2 mRNA over-expression (P = 8.2 × 10−9, fold-change = 5.6, Fig. 1b), but also altered the transcript and protein structure. AAV2 and HBV insertions induced the expression of various abnormal transcripts (Supplementary Fig. 1), predicted to generate a truncated cyclin A2 protein starting at methionine 148 or 158 with occasionally a few amino acids translated from the viral genome (Fig. 1c).

Fig. 1
Fig. 1

Diverse mechanisms leading to CCNA2 activation in HCC. a Summary of structural rearrangements (top) and viral insertions (bottom) affecting CCNA2 gene identified in 751 HCC from the LICA-FR, TCGA and ICGC-JP cohorts. b Sorted CCNA2 expression (log scale) in the LICA-FR and TCGA cohorts. Gene expression was obtained from RNA-seq data and is given in fragments per kilobase of exons per million reads (FPKM). Samples harboring structural variants (SV) or viral insertions are indicated with a color code. c Functional consequences of AAV2 and HBV insertions in CCNA2. Viral insertions identified in the LICA-FR cohort were precisely mapped using WGS or viral capture data, and RNA-seq reads were aligned on the reconstructed chimeric DNA to identify the transcription start sites and predicted translation initiation sites of abnormal transcripts. d CCNA2 fusions identified in the LICA-FR, TCGA and ICGC-JP cohorts. The transcription start site of the fusion transcript is represented together with the predicted translation initiation site. Fusions with KIAA1109, LIPC and TDO2 involve 5′ exons not annotated in transcript databases but expressed in normal liver. e Schematic representation of cyclin A2 protein with functional domains. D-box Destruction box; Ub, Ubiquitination targeting sequences. f Western blot analysis of cyclin A2 using antibodies targeting the N-terminal (top) or C-terminal (middle) domains. Tumors with viral insertions or gene fusions are compared with tumors without CCNA2 alteration and non-tumoral liver controls

In addition we identified novel gene fusions in 4 tumors (Supplementary Data 4), all involving the C-terminal part of CCNA2 (exons 3–8) at chromosome 4q27 downstream 3 different partner genes: GSTCD at 4q24, SNX29 at 16p13.13 and TET2 (×2) at 4q24 (Fig. 1a, d). In the TET2-CCNA2 and GSTCD-CCNA2 fusion transcripts, the first untranslated exons of TET2 and GSTCD were linked with CCNA2 exons 3–8. The SNX29-CCNA2 fusion revealed an alternative transcription start site (TSS) in SNX29 intron 14 generating a 448-nucleotide sequence spliced with CCNA2 exon 3. In all fusions, the predicted translation initiation site of the fused RNA was located at methionine 158 in CCNA2 exon 3, predicted to generate a truncated cyclin A2 protein of 275 amino acids (32 Kda), lacking the destruction box18 and ubiquitination targeting sequences19 but retaining the functional cyclin box, without any protein fragment from the partner genes (Fig. 1e).

Western blot analysis of 9 tumors with viral insertion or gene fusion confirmed the over-expression, as predicted, of a truncated 32 KDa protein (Fig. 1f). Thus, gene fusions and viral insertions in CCNA2 both lead to the production of a stable protein lacking the N-terminal regulatory domains.

In the TCGA series, we identified 7 CCNA2 fusions with 5 different partner genes (FAM160A1, KIAA1109 × 3, LIPC, UBA6 and TDO2, Fig. 1a, d), all of which involved the first untranslated exon(s) of the partner gene linked with exons 3–8 of CCNA2. WGS revealed in another tumor a focal deletion starting in the 5′ UTR region and ending in CCNA2 intron 2 (Supplementary Fig. 2). All these events were predicted to generate the same 32 KDa truncated cyclin A2 protein lacking N-terminal regulatory domains. We also identified one tumor with HBV insertion and 3 tumors with AAV2 insertions in CCNA2. Finally, 6 tumors strongly overexpressed CCNA2 (FPKM > 15), 3 of which displayed 23–48 Mb intra-chromosomal deletions linking the intergenic region downstream CCNA2 with the highly expressed ALB, AFP, and ADH6 genes (Supplementary Fig. 2). The ICGC-JP cohort comprised one HBV insertion in CCNA2 intron 2 and one fusion between the first untranslated exon of ANXA5 and exons 3–8 of CCNA2 (Fig. 1a, d).

In total, we identified 10 HCC with CCNA2 activation events in the LICA-FR series (6.2%), 2 in the ICGC-JP series (0.8%) and 18 in the TCGA series (5.4%), associated with a significant increase of CCNA2 mRNA expression, but also generating a truncated cyclin A2 protein lacking the N-terminal destruction box and the ubiquitination site.

Viral insertions and enhancer hijacking activate cyclin E1

In our series of 160 HCC, we identified 5 AAV2 insertions (three previously described in the ref. 16) and one HBV insertion in the 5′ region or upstream the transcription start site (TSS) of CCNE1 (Fig. 2a, Supplementary Data 3). These viral insertions induced a massive overexpression of the full-length CCNE1 gene (Fig. 2b), confirmed by western-blot analysis (Supplementary Fig. 3). Interestingly, one case with AAV2 insertion (FR2141T) also displayed an amplification of CCNE1 locus including the viral sequence (Supplementary Fig. 3), suggesting a two-step selection of CCNE1 activation in the natural history of this tumor. Four other tumors overexpressed CCNE1 (FPKM > 6), explained by high-level amplification in one case. In the 3 remaining cases, whole genome sequencing revealed interchromosomal translocation breakpoints in the regulatory region of CCNE1 (Fig. 2a). Tumor FR2048T displayed a translocation placing CCNE1 downstream the first untranslated exon of the highly expressed ERRFI1 gene, leading to a highly expressed ERRFI1-CCNE1 fusion. The two other translocations lead to juxtapose CCNE1 promoter with enhancer-rich chromatin areas located close to the highly expressed genes RAPH1 and CYB5A (Fig. 2c). Thus, both viral insertions and structural rearrangements can activate CCNE1 expression by bringing viral or distal human enhancers in the regulatory region of the gene.

Fig. 2
Fig. 2

Viral and non-viral mechanisms of CCNE1 activation in HCC. a Summary of structural rearrangements (top) and viral insertions (bottom) affecting CCNE1 gene identified in 751 HCC from the LICA-FR, TCGA and ICGC-JP cohorts. b Sorted CCNE1 expression (log scale) in the LICA-FR and TCGA cohorts. Gene expression was obtained from RNA-seq data and is given in fragments per kilobase of exons per million reads (FPKM). Samples harboring structural variants (SV), focal amplifications and viral insertions are indicated with a color code. c Functional consequences of structural rearrangements affecting CCNE1 regulatory region. RNA-seq read counts along CCNE1 locus are represented in normal liver (top) and in 4 tumors harboring structural rearrangements upstream CCNE1 trancription start site (TSS). H3K27Ac chromatin immunoprecipitation sequencing (ChIP-seq) signal and chromatin states in adult liver were obtained from the ROADMAP consortium and are depicted below each reconstruted DNA sequence. EnhA: active enhancer; EngG: genic enhancer; EnhWk: weak enhancer; TssA: active TSS; TssFlnk: flanking TSS; TxWk: weak transcription; Quies: quiescent chromatin

In the TCGA series, 10 tumors overexpressed CCNE1 (Fig. 2b), including 2 cases with HBV insertion, one with HBV insertion plus high-level amplification, one with AAV2 insertion and one with a translocation between CCNE1 regulatory region and an enhancer-rich region on chromosome 5 (Fig. 2c). In the 5 remaining cases, the mechanism leading to CCNE1 overexpression remained unexplained in absence of WGS data. In the ICGC-JP cohort, we identified one AAV2 and one HBV insertion associated with CCNE1 overexpression. In total, we identified 10 HCC with CCNE1 activation events in the LICA-FR cohort (6.2%), two in the ICGC series (0.8%) and 10 in the TCGA series (3.0%).

Across the three data sets, 52/751 tumors (6.9%) displayed an activation of cyclin A2 (n = 30) or E1 (n = 22) due to viral insertions or structural rearrangements. These are later referred to as CCN-HCC. The proportion of CCN-HCC varied between the cohorts (12.5% in our series, 8.4% in TCGA and 1.6% in ICGC-JP) due to differences in etiological backgrounds (Supplementary Data 2). It was particularly high in our series enriched in cancers developed in a non-fibrotic liver, and low in the IGGC-Japan series dominated by HCV-related cases.

Cyclin A2 or E1 activation defines a homogenous HCC subgroup

We next explored the molecular and clinical characteristics of CCN-HCC. Gene expression analysis of the LICA-FR and TCGA showed that CCN-HCC defined homogeneous transcriptional clusters (Fig. 3a). They were characterized by an overexpression of cell cycle genes, in particular E2F targets, and an activation of the ATR pathway in response to replication stress (Fig. 3b, Supplementary Data 5). The most significant down-regulated pathways were oxidative phosphorylation, suggesting a metabolic switch to aerobic glycolysis (Warburg effect), and MYC targets. We also compared the alteration frequencies of known liver cancer driver genes10 between CCN-HCC and others. CCNA2 and CCNE1 activation events were remarkably exclusive from CTNNB1 and TERT promoter mutations, but frequently associated with PTEN and RB1 inactivation in both the LICA-FR and TCGA series (Fig. 3b, Supplementary Data 6). RB1 inactivation may allow cells to overcome oncogene-induced senescence20 in these tumors, whereas PTEN inactivation might favor the oncogenic metabolic switch that we observed at the transcriptional level21. Compared to the other tumors in the LICA-FR series, CCN-HCC were enriched in large tumors (median largest nodule diameter = 115 vs. 60 mm, P = 0.0033), of poor prognosis (median overall survival = 21 vs. 69 months, P = 0.0072, Fig. 3c), developed in younger patients (median age = 57 vs. 67 years old, P = 0.050) with a non-fibrotic liver (fibrosis stage F0-F1 80 vs. 42%, P = 0.0011). Thus, CCN-HCC define a homogenous HCC entity with characteristic clinical and molecular features.

Fig. 3
Fig. 3

Clinical and molecular features of cyclin-activated HCC. a t-SNE plots depicting the classification of HCC from the LICA-FR and TCGA cohorts based on their transcriptional profiles. Tumors harboring CCNA2 or CCNE1 activating alterations are indicated with a color code. b Clinical characteristics, driver genes and deregulated pathways associated with CCN-HCC in the LICA-FR (top) and TCGA (bottom) cohorts. c Overall survival in CCN-HCC as compared with other HCC in the LICA-FR cohort. Only HCC with curative resection (R0) were included

CCN-HCC display a unique structural rearrangement signature

To identify mutational signatures associated with CCN-HCC, we analyzed the whole genome sequences of 45 of our 160 HCC (35 were previously published22, 10 new), including 13 CCN-HCC. With a median of 12,463 mutations, CCN-HCC were rather less mutated than others (median = 16,397 mutations, P = 0.065). Mutational signatures 4, 5, and 16 (COSMIC nomenclature), ubiquitous in liver cancers22, accounted for most mutations in CCN-HCC, with a slight increase of signature 5 (53 vs. 33%, P = 0.036) and decrease of signature 16 (23 vs. 32%, P = 0.05) as compared with other HCC (Supplementary Fig. 4).

In contrast, CCN-HCC displayed > 3 times more structural variants (median = 415 vs. 126, P = 1.1 × 10−4). We identified 6 rearrangement signatures, termed RS1 to RS6, characterized by different combinations of rearrangement categories defined according to the type, size, and clustered nature of rearrangements (Fig. 4a). Strikingly, a high number of rearrangements attributed to signature RS1 (≥50 events) was specifically encountered in a cluster of 13 tumors corresponding exactly to CCN-HCC (P = 1.4 × 10−11, Fig. 4b). We validated this association using WGS data from the ICGC-JP series and a subset of 48 samples from the TCGA series (Fig. 4c, Supplementary Data 7). In absence of WGS data for the rest of the TCGA series, we used SNP array data to estimate the number of focal gains (<200 kb) in each tumor as a surrogate marker of the RS1 signature. With a median of 120 events, CCN-HCC displayed a significant increase of focal gains as compared with other HCC in the TCGA series (median = 6, P < 2.2 × 10−16, Supplementary Fig. 5). Thus, CCN-HCC have a relatively low mutation burden but a large number of structural rearrangements with a specific signature.

Fig. 4
Fig. 4

Cyclin-activated HCC display a specific signature or structural rearrangements. a Six rearrangement signatures identified across 350 HCC genomes by non-negative matrix factorization. Structural rearrangements were classified in 38 categories considering their type (del: deletion, dup: tandem duplication, inv: inversion, trans: inter-chromosomal translocation) and size, and distinguishing clustered from non-clustered events. The probability of each rearrangement category in each signature is represented, with rearrangement types indicated above and rearrangement sizes below. b Unsupervised classification of 45 HCC from the LICA-FR cohort based on the contribution of rearrangement signatures in each tumor. Significant molecular alterations associated with the cluster of tumors having a high contribution of signature RS1 are represented below. P-values were obtained using Fisher’s exact tests. c Validation of the association between the RS1 signature and CCN-HCC in the TCGA and ICGC-JP series. The middle bar, median; box, interquartile range; bars extend to 1.5 times the interquartile range. d CIRCOS plot representing the structural rearrangement profile of a representative CCN-HCC (FR-961T, harboring a GSTCD-CCNA2 fusion). e Copy-number profile showing the accumulation of focal gains along chromosome 14 in tumor FR-961T. Structural rearrangements are overlaid on the copy-number profile with a color code indicating the type of event. trans: inter-chromosomal translocation; dup: tandem duplication; inv: inversion. f Three types of rearrangements leading to focal chromosome gains in CCN-HCC. A representative example of each type of event is shown with a copy-number plot above and a schematic representation of the rearranged chromosome below. Structural rearrangements are represented with the same color code as in e. Dashed lines on schematic chromosome reconstructions represent the abnormal junctions detected in WGS data

RS1 features suggest a replication stress-induced mechanism

Almost all rearrangements in CCN-HCC belonged to signature RS1, characterized by a combination of small tandem duplications (<100 kb) and inter-chromosomal translocations (Fig. 4d). CCN-HCC also displayed a typical copy-number profile showing hundreds of focal gains, usually one copy above surrounding chromosome segments (Supplementary Fig. 6). Surprisingly, overlaying structural rearrangement breakpoints with copy-number profiles revealed that only 68% of these gains were due to tandem duplications, other gains being frequently surrounded by translocation or inversion breakpoints (Fig. 4e, Supplementary Fig. 6). A recurrent feature consisted of several chromosome segments, usually between 10 and 100 kb, stung together and with the same duplication level relative to their source chromosomes. Most of these events involved segments from two (Fig. 4f) or more (Supplementary Fig. 7) different chromosomes, a feature recently described as templated insertion cycle23. Inter-chromosomal templated insertions accounted for 11% of focal gains in CCN-HCC. Other events, which we call intra-chromosomal templated insertions, involved distal segments of a same chromosome and appeared as couples of inversions (Fig. 4f) or duplication and deletion (Supplementary Fig. 7), depending on the orientation of the junctions. Intra-chromosomal templated insertions accounted for 7% of focal gains in CCN-HCC. All these events are consistent with a replication-based mechanism in which a DNA polymerase at a stalled replication fork would switch template, replicate one or more other DNA regions and switch back to the original template strand behind the point of departure, generating a duplication on the host chromosome23,24,25,26. Such mechanism could be particularly active in CCN-HCC due to replication stress induced by premature S phase entry.

Structural rearrangements activate TERT promoter in CCN-HCC

To better understand the functional consequences of the rearrangement phenotype observed in CCN-HCC, we examined the location of 8466 breakpoints attributed to the RS1 signature among the 350 liver cancer genomes from the LICA-FR, TCGA and ICGC cohorts. RS1 breakpoints were not distributed evenly along the genome but formed clusters located almost exclusively within active topologically associated domains (TADs, Fig. 5a) characterized by early replication, high gene expression and active chromatin states in normal liver (Fig. 5b). In particular, RS1 breakpoint hotspots were frequently observed at loci encoding very highly expressed liver enzymes exemplified by the albumin (ALB), alcohol dehydrogenase (ADH) and hydroxysteroid 17-Beta dehydrogenases (HSD17B) loci on chromosome 4 (Fig. 5a, Supplementary Fig. 8). Among the 18 chromatin states defined by the ROADMAP consortium in normal adult liver, active transcription start sites (TSS) and enhancer regions were the most strongly enriched in RS1 breakpoints (fold-change > 3), whereas quiescent and heterochromatin domains were the most depleted (Fig. 5c). TSS and enhancer regions were also enriched, to a lesser extent, in breakpoints related to signature RS2 characterized by large tandem duplications. By contrast, breakpoints related to signature RS6, dominated by inversions < 10 kb, were predominantly observed in heterochromatin and ZNF repeats.

Fig. 5
Fig. 5

Hotspot analysis of rearrangement signature 1 (RS1) breakpoints. a The density of RS1 breakpoints along chromosome 4 is displayed above replication timing, RNA-seq expression, H3K27Ac ChIP-seq profile and chromatin state. Replication timing was determined using Repli-Seq data from the liver cancer cell line HepG2. RNA-seq profile was generated from a normal liver sample. H3K27Ac and chromatin states in normal adult liver were obtained from the ROADMAP consortium. The legend for chromatin state color codes is displayed in c. Hotspots corresponding to highly expressed liver enzymes are annotated (UGDH, UDP-glucose 6-dehydrogenase; UGT, UDP glucuronosyltransferase family cluster; ALB, albumin; HSD17B, hydroxysteroid 17-Beta dehydrogenases 11 and 13, ADH, alcohol dehydrogenase cluster; ACSL1, acyl-CoA synthetase long chain family member 1). b RS1 breakpoint density in topologically associated domains (TADs). TADs were defined in human embryonic stem cells (H1) and classified based on gene expression in normal liver, replication timing and chromatin state. For each comparison, breakpoint density was normalized to be 1 in the group with the lowest density. Error bars indicate the 95% confidence interval. c Enrichment of rearrangement breakpoints in ROADMAP chromatin states for the 6 rearrangement signatures identified in HCC. For each signature, the fold-change between the observed and expected number of breakpoints falling within each chromatin state is represented, and chromatin states with a >2-fold enrichment are annotated. d Quantile-quantile plot of RS1 breakpoint enrichment p-values across 500 kb windows. e Proportion of TERT promoter alterations in CCN-HCC and other HCC analyzed by WGS. f Contribution of the 6 rearrangement signatures to TERT promoter rearrangements in CCN-HCC and other HCC

We then used binomial regression27 to model the density of rearrangement breakpoints along the genome considering an extensive set of genomic features (Supplementary Fig. 9) and to identify hotspots harboring more breakpoints than expected by chance from the background model, which may indicate positive selection in CCN-HCC. We identified a single significant locus corresponding to TERT promoter region (q=0.0029, Fig. 5d). Although TERT promoter mutations were rare in CCN-HCC (9 vs. 55% in others, P = 2.4 × 10−5), TERT promoter rearrangements were highly enriched (82 vs. 7%, P = 1.8 × 10−15, Fig. 5e) and involved regions of active chromatin in normal liver, in the vicinity of highly expressed liver enzymes (ALB, FGG, SEP15, SLC12A7 and BAAT) or transcription factors (HNF4A, CEBPA, and CEBPB) (Supplementary Data 8, Supplementary Fig. 10). TERT promoter rearrangements induced an overexpression of TERT, stronger than promoter mutations but lower than HBV insertions (Supplementary Fig. 11). Of the 18 TERT promoter rearrangements identified in CCN-HCC, 16 could be associated with signature RS1 with a probability ≥ 0.5 (Fig. 5f). By contrast, most TERT promoter rearrangements in other HCC were related to signature RS4. Thus, structural rearrangements induced by replication stress are enriched at active chromatin regions and can promote CCN-HCC development by activating oncogenes like TERT.

CCN-HCC share a similar signature with BRCA1-altered cancers

To investigate the prevalence of the RS1 signature in other cancer types, we applied our method to 2606 tumors from the ICGC PanCancer Analysis of Whole Genomes (PCAWG) dataset23,28,29. In this pan-cancer series, we identified 9 rearrangement signatures (Supplementary Fig. 12), including one signature (RS1-pancan) highly similar to the RS1 signature that we identified in liver cancers (cosine similarity = 0.91). The RS1-pancan signature was detected at low frequency in several cancer types (e.g. bladder, lung, esophageal and gastric cancers), and was highly active in breast (18% of samples with ≥ 50 RS1 events) and ovarian (33%) cancers. However, this signature was associated with CCNA2/E1 rearrangements only in liver cancer (Fig. 6a, Supplementary Data 9). Thus, the relationship between cyclin A2/E1 activation and signature RS1 is specific to liver cancer, and the molecular cause of this signature in other cancer types remains to be elucidated. In ovarian and breast cancer, RS1 signature was not associated with CCNE1 amplifications but with BRCA1 inactivation (Fig. 6b, c), consistent with previous reports30,31. Despite sharing a common signature of short tandem duplications and templated insertions, CCNA2, CCNE1 and BRCA1-altered tumors displayed slightly different characteristics. First, the number of RS1 rearrangements was higher in CCNA2-activated HCC (median = 269) than in CCNE1-activated HCC (137) and BRCA1-altered breast (132) and ovarian (159) cancers (Fig. 6d). Second, tandem duplications were larger in CCNE1-activated HCC (median = 39 kb) than in CCNA2-activated HCC (22 kb), and smaller in BRCA1-altered breast (9 kb) and ovarian (10 kb) cancers (Fig. 6e). Finally, duplication and translocation breakpoints were strongly enriched in early-replicated regions in CCN-HCC as compared with other HCC, but not in BRCA1-altered as compared with other breast and ovarian cancers (Fig. 6f). Cyclin E1 activation was recently shown to induce replication stress by firing novel replication origins located within highly transcribed genes and prone to collapse32. BRCA1 is implicated in the response to replication stress33,34 and its inactivation leads to tandem duplication formation at stalled forks by a replication restart-bypass mechanism35. Cyclin A2/E1 activation in HCC and BRCA1 inactivation in breast and ovarian cancers may thus converge towards a similar rearrangement signature, with specificities reflecting the different ways by which these genetic alterations induce replication stress or modulate response to it (Fig. 6g).

Fig. 6
Fig. 6

Pan-cancer analysis of the RS1 signature a Violin plots representing the number of rearrangements attributed to signature RS1 across patients within each cancer type in the ICGC PCAWG data set. For each cancer type, we assessed the association between tumors with ≥ 50 RS1 events and tumors with a rearrangement breakpoint < 80 kb from CCNA2 or CCNE1 gene using Fisher’s exact tests. ns: not significant. The definition of cancer codes and number of samples per cancer type are available in Supplementary Data 9. b Number of RS1 events across 524 breast cancer genomes30 and association with BRCA1 alterations and CCNE1 amplifications. PD13296a, the only tumor with both BRCA1 mutation and CCNE1 amplification, has the highest number of RS1 events in the series. c Number of RS1 events across 80 ovarian cancer genomes75 and association with BRCA1 alterations and CCNE1 amplifications. P-values were obtained using one-sided Wilcoxon rank-sum tests. d Number of RS1 events in liver, breast and ovarian cancers with or without CCNA2, CCNE1 and BRCA1 alterations. The middle bar, median; box, interquartile range; bars extend to 1.5 times the interquartile range. e, Violin plots representing the distribution of tandem duplication sizes across liver, breast and ovarian cancers with or without CCNA2, CCNE1 and BRCA1 alterations. f Violin plots representing the replication timing of duplication and inter-chromosomal translocation breakpoint loci in liver and breast cancers with or without CCNA2, CCNE1 and BRCA1 alterations. Replication timing was determined using Repli-Seq data from the HepG2 cell line for liver cancer and from the MCF-7 cell line for breast cancer. g Proposed connexion beween rearrangement signatures in CCN-HCC and in BRCA1-inactivated breast and ovarian cancers


Here, we report the characterization of a homogeneous HCC subgroup driven by the activation of CCNA2 or CCNE1 gene. CCN-HCC represent 7% of HCC across the 3 data sets analyzed here, but up to 14% of HCC developed in a non-fibrotic liver. These patients often have atypical clinical presentation, without any history of primary risk factors, and can be remarkably young, exemplified by tumor FR-3880T developed in a 32 year-old woman without any risk factor, due to a TET2-CCNA2 fusion. CCN-HCC are usually large tumors of poor prognosis but share molecular characteristics, in particular high proliferation and replication stress, that could provide therapeutic opportunities36. First, conventional chemotherapies mainly affect actively dividing cells by generating DNA damage or blocking DNA replication, and the tandem duplicator phenotype was identified as a marker for chemotherapeutic response in breast cancer cell lines and patient-derived xenografts37. Transarterial chemoembolization (TACE) with doxorubicin, cisplatin or epirubicin, usually recommended for patients with intermediate HCC not eligible for surgery, may thus be an interesting option for CCN-HCC. Poly(ADP-ribose) polymerase (PARP) inhibitors, the first clinically approved drugs designed to exploit synthetic lethality, have demonstrated benefit for patients carrying BRCA1 mutations38. CCN-HCC do not harbor a DNA repair defect but share with BRCA1-altered tumors a signature of genomic instability that could conceivably confer these tumors sensitivity to PARP inhibitors. Finally, there are currently several compounds in phase I and II trials targeting the replication stress response pathway members ATR, CHK1 and WEE139. If brought to the clinic, such compounds would be promising for CCN-HCC treatment, given that the ATR pathway is strongly upregulated in CCN-HCC and overexpression of CCNE1 has been shown to confer increased sensitivity to ATR inhibition40.

We describe for the first time recurrent fusions involving CCNA2 gene and recurrent rearrangements of CCNE1 promoter region. CCNA2 fusions are only the second recurrent fusion event identified in hepatocellular carcinoma, after the PRKACA-DNAJB1 fusion characteristic of the rare fibrolamellar carcinoma subtype41. These fusions always involve the untranslated 5′ region of different partner genes upstream exons 3–8 of CCNA2, which constitutes an original mechanism leading to oncogene activation by truncating a regulatory N-terminal domain. Apart from liver cancers, none of the 2606 tumor genomes from the ICGC PCAWG dataset displayed a rearrangement breakpoint in CCNA2 intron 2. Consistently, a recent RNA-seq analysis of 9,624 TCGA samples from 33 cancer types42 did not reveal any CCNA2 fusion in other cancer types. CCNA2 fusions thus appear to be specific of liver cancers. Rearrangements affecting CCNE1 promoter region result in the overexpression of cyclin E1 by bringing active enhancer regions upstream the transcription start site, mirroring the effect of viral enhancers. This mechanism was more frequent than CCNE1 amplification in the liver cancer series we analyzed. Although HBV and AAV2 insertions were previously identified in CCNA2 and CCNE114,16, the functional consequences of these insertions were unknown. By integrating WGS and RNA-seq data, we demonstrate here that viral insertions in CCNA2, like gene fusions, induce abnormal transcripts leading to truncated proteins lacking N-terminal regulatory domains. By contrast, viral insertions in CCNE1 region lead to the overexpression of a full-length transcript and protein.

CCN-HCC display a characteristic transcriptional program, with a strong overexpression of E2F targets. Activation of the E2F pathway is expected in RB1-altered tumors and was already described in HCC43. However, E2F pathway is also activated in CCN-HCC without RB1 inactivation event and may be partly explained by the ability of cyclin E/Cdk2 complexes to phosphorylate Rb. Interestingly, E2F-1 overexpression in the liver causes dysplasia and tumors in mice43, and E2F1 was shown to inhibit c-Myc-driven apoptosis by activating PIK3CA/Akt/mTOR and c-Myb/COX-2 pathways44.

A striking feature of CCN-HCC is the accumulation of hundreds of tandem duplications and templated insertion cycles. A recent study showed that CCNE1 activation in U2OS cell lines leads to shortened G1 phase, early S phase entry and firing of normally silenced replication origins in highly expressed genes, prone to collapse and associated with DNA double-strand breaks formation32. Double-strand breaks formed following replication fork breakdown are primarily repaired by break-induced replication (BIR)45. In a cyclin E overexpression model of DNA replication stress, BIR was shown to be required for cell cycle progression and to induce duplications < 200 kb46. In addition, template switching may occur during BIR and generate complex chromosome rearrangements24,25,47. Thus, the nature of rearrangements identified in CCN-HCC and the enrichment of breakpoints in early-replicated, actively transcribed regions are consistent with a BIR mechanism induced by replication stress. However, future studies addressing the precise molecular mechanism generating templated insertions will be crucial to fully understand the relationship between replication stress and the RS1 rearrangement signature. The mechanism of tandem duplication formation in BRCA1-mutant cells was recently identified35. It involves abnormal repair of collapsed replication forks by a “replication restart bypass” mechanism with extension of the stalled leading strand by a migration bubble mechanism similar to BIR48, terminated by end joining or by microhomology-mediated template switching. Thus, structural rearrangements induced by cyclin activation and BRCA1 deficiency are initiated by replication fork collapse and processed by different repair mechanisms leading to a similar rearrangement signature with subtle differences regarding the size of rearrangements and breakpoint location. Interestingly, BRCA1 inactivation and CCNE1 amplification are mutually exclusive in ovarian cancers49, and have been shown to be synthetically lethal50. The single breast tumor that we identified with both BRCA1 mutation and CCNE1 amplification (PD13296a) had the highest number of rearrangements related to the RS1 signature (n = 1221) across all the tumors we analyzed.

Contrary to CCNA2 alterations that seem to be specific of liver cancers, CCNE1 activation by high-level amplification is frequent across human cancers, in particular in gynecologic cancers51. Yet, CCNE1 amplification in breast and ovarian cancers does not lead to the rearrangement phenotype that we observed in CCN-HCC. Several reasons may explain this discrepancy. First, adult hepatocytes are quiescent, rarely divide, and may thus be particularly sensitive to replication stress. Second, CCNE1 is mostly activated by viral insertions and structural rearrangements of regulatory regions in HCC, rather than chromosome amplifications. These alterations may not have exactly the same functional consequence. Finally, we believe that viral insertions and structural rearrangements activating CCNA2 or CCNE1 are early events triggering hepatocarcinogenesis because they occur in patients without cirrhosis and in absence of other oncogenic event like CTNNB1 mutations. CCNE1 amplifications may occur later in breast and ovarian tumors, not leaving enough time for rearrangements to accumulate. Fujimoto et al. reported a positive correlation between the number of structural rearrangements and HBV insertion sites, suggesting that double-strand breaks generated by structural rearrangements may provide opportunities for HBV integration11. Here we describe the reciprocal relationship where viral insertions in cyclin genes lead to structural rearrangement formation due to replication stress.

The propensity of signature RS1 breakpoints to occur in enhancer-rich regions makes these rearrangements likely to activate oncogenes in trans. In this limited series of 22 CCN-HCC analyzed by WGS, we identified a single significantly recurrent hotspot at TERT promoter. However, the power to identify recurrent somatic rearrangement hotspots increases sharply with sample size27, and future studies of larger CCN-HCC series may uncover additional sites under positive selection in CCN-HCC.

In conclusion, viral insertions and structural rearrangements activating CCNA2 and CCNE1 define a homogeneous subgroup of aggressive HCC developed in non-cirrhotic liver, sharing similar transcriptional profiles and frequent inactivation of RB1 and PTEN. These tumors display a specific rearrangement signature induced by replication stress that sustains tumor growth by activating TERT but may constitute a targetable vulnerability.


Description of the LICA-FR cohort

A series of 160 hepatocellular carcinoma (HCC) samples and their non-tumor counterparts were collected from patients surgically treated in four French hospitals located in Bordeaux and Paris region. The study was approved by institutional review board committees (CCPRB Paris Saint-Louis, 1997, 2004, and 2010, approval number 01–037; Bordeaux, 2010-A00498–31). Written informed consent was obtained in accordance with French legislation. All samples were immediately frozen in liquid nitrogen and stored at −80 °C. HCC were enriched in cases developed on a non-cirrhotic liver (107/160, 67%): 75 tumors developed in non-fibrotic (METAVIR F0-F1), 32 in chronic hepatitis (F2–F3) and 53 in cirrhotic liver (F4). Clinicopathological data were available for all cases. A diversity of risk factors were represented in our series, including alcohol (n = 63), metabolic syndrome (n = 37), HBV (n = 30), and HCV infection (n = 30). Twenty-nine patients had none of the above risk factors. These 160 samples were analyzed by RNA sequencing, 156 were analyzed by whole exome sequencing (including 96 were previously published10) and 45 by whole genome sequencing (35 were previously published22). Detailed clinical characteristics and sequencing details for each sample are provided in Supplementary Data 1.

Whole genome sequencing

Whole genome data from 45 tumors of the LICA-FR series were analyzed in this study, comprising 35 previously published22 and 10 new cases. The whole genomes of 10 new tumor/normal pairs were sequenced for this project at the Center National de Recherche en Génomique Humaine (CNRGH, Evry, France) on an Illumina HiSeq X Five as paired-end 151 bp reads. Sequences were aligned to the hg19 version of the human genome using BWA52 version 0.7.12. We used Picard tools version 1.108 (http://broadinstitute.github.io/picard/) to remove PCR duplicates and GATK53 version v3.5 for local indel realignment and base quality recalibration, as recommended in GATK best practices54. We obtained an average depth of 119-fold for tumors (range 104–126) and 41-fold for matched non-tumor liver samples (range 38–43).

Whole exome sequencing

Whole exome data from 156 tumors of the LICA-FR series were analyzed in this study, comprising 96 previously published10 and 60 new cases. Sequence capture, enrichment and elution of genomic DNA samples from the 60 new tumor/normal pairs was performed by IntegraGen (Evry, France). Agilent in-solution enrichment was used with the manufacturer’s biotinylated oligonucleotide probe library SureSelect Human All-Exon kit v5 + UTRs (n = 39) or SureSelect Clinical Research Exome V2 (n = 21) according to the manufacturer’s instructions. The eluted enriched DNA sample was sequenced on an Illumina HiSeq 2000 (n = 39) or HiSeq 4000 (n = 21) as paired-end 75 bp reads. Sequencing details for each sample are indicated in Supplementary Data 1.

Somatic mutation calling

We used MuTect2 to call somatic mutations from WES and WGS data by comparing each tumor sample with its matched non-tumor counterpart and a panel of normals (PON) file. We excluded mutations belonging to the ENCODE Data Analysis Consortium blacklisted regions (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeMapability/wgEncodeDacMapabilityConsensusExcludable.bed.gz) and regions covered by < 6 reads in the tumor or normal sample. We then selected only single nucleotide variants (SNVs) with a MuTect2 flag among “PASS”, “clustered_events”, “t_lod_fstar”, “alt_allele_in_normal” or “homologous_mapping_event” and small insertions and deletions (indels) with a MuTect2 flag among “PASS”, “clustered_events” or “str_contraction”. To improve specificity in the calling of mutations with low variant allele frequency (VAF), we quantified the number of high quality variant reads in the tumor (mapping quality ≥ 20, base quality ≥ 20) and the number of variant reads in the non-tumor sample with no quality threshold using bamreadcount (https://github.com/genome/bam-readcount). Only variants matching the following criteria were finally retained: VAF ≥ 2% in the tumor with ≥ 3 variant reads, VAF ≤ 5% in the non-tumor samples with ≤ 2 variant reads, and a VAF ratio ≥ 5 between the tumor and non-tumor sample.

Copy-number and structural rearrangement analysis

We used MANTA55 software to identify somatic structural rearrangements in WGS data. To keep only the most reliable events, we selected only rearrangements supported by ≥ 10 reads and with a variant allele fraction ≥ 5%. We used cgpBattenberg56 algorithm to reconstruct copy-number profiles from WGS data. We used the circular binary segmentation algorithm implemented in the Bioconductor package DNAcopy57 to reconstruct copy-number profiles from WES data.

RNA sequencing

RNA samples from the 160 tumors of the LICA-FR series were sequenced in several batches with slightly different protocols. RNA samples were enriched for polyadenylated RNA from 5 μg of total RNA, and the enriched samples were used to generate sequencing libraries with the Illumina TruSeq or Illumina TruSeq Stranded mRNA kit and associated protocol as provided by the manufacturer. Libraries were sequenced by IntegraGen (Evry, France) on an Illumina HiSeq 2000 or 4000 as paired-end 75 or 100 bp reads. Full Fastq files were aligned to the reference human genome hg19 using TopHat258. Sequencing details for each sample and the parameters used for TopHat2 are indicated in Supplementary Data 1. We removed reads mapping to multiple locations, and we used HTSeq59 to obtain the number of reads associated to each gene in the Gencode v19 database, restricting to protein-coding genes, pseudogenes, antisense and lincRNAs (n = 42540). We used the Bioconductor DESeq2 package60 to import raw HTSeq counts for each sample into R statistical software and apply variance stabilizing transformation (VST) to the raw count matrix. FPKM scores (number of fragments per kilobase of exon model and millions of mapped reads) were calculated by normalizing the count matrix for the library size and the coding length of each gene. We used the area under the ROC curve (AUC) to identify and remove 2724 genes with a significant batch effect (AUC > 0.95 between one sequencing project and others).

Gene fusion detection

Fusions detected by TopHat2 (--fusion-search --fusion-min-dist 2000 --fusion-anchor-length 13 --fusion-ignore-chromosomes chrM) were filtered using the TopHatFusion-post algorithm. We kept only fusions validated by BLAST and with at least 10 split-reads or pairs of reads spanning the fusion event, and we removed fusions identified at least twice in a cohort of 36 normal liver samples.

Gene expression analysis

We used t-distributed stochastic neighbor embedding (t-SNE) to classify HCC based on their gene expression profiles. We selected the 1000 most variably expressed genes, and we used 1 minus the weighted Pearson correlation coefficient as the distance measure. Pairwise Pearson correlation was calculated using the wtd.cors function of the weights R package. We used standard deviation substracted by 0.2 as the weight, giving more variable genes greater influence. The resulting distance matrix was used to perform the t-SNE analysis using the R package Rtsne61 with default parameters except the following: theta = 0, is_distance = T, pca = F, max_iter = 2000. We used the Bioconductor limma package62 to test for differential expression between CCN-HCC and other HCC of all genes expressed in at least five samples (FPKM > 0). We applied a q-value threshold of ≤ 0.05 to define differentially expressed genes. We used an in-house adaptation of the GSEA method63 to identify gene sets from the MSigDB v6 database overrepresented among upregulated and downregulated genes.

Viral insertion screening

AAV2 insertions had previously been screened by viral capture and whole exome sequencing in 83 tumors from the LICA-FR cohort16. We extended this screen to AAV2 and HBV insertions in all HCC from the LICA-FR cohort using RNA-seq and WES data. In the ICGC-JP cohort, AAV2 and HBV insertions had already been screened using WGS data and were provided by Fujimoto et al.11 In the TCGA cohort, we screened AAV2 and HBV insertions using RNA-seq data from all tumors and WES data from 37 tumors showing viral reads or overexpression of CCNA2 or CCNE1 in RNA-seq data. For each tumor and matched normal sample, the sequence reads were mapped to the AAV2 (AF043303.1) and HBV (X02763, renumbered using the EcoR1 restriction site as the +1) reference genomes using BWA52. Read pairs with at least one read aligned on the virus were extracted using samtools64, and aligned to a custom reference genome including human chromosomes and virus fasta sequences as pseudo-chromosomes. Tumors with ≥ 6 chimeric reads or read pairs aligned on both the human and viral genomes were further analyzed. All viral insertions were validated by visual inspection on IGV65. We used chimeric reads to identify insertion breakpoints at base resolution by mapping sequences on both sides of the junctions. Of the 12 LICA-FR tumors with viral insertions detected in CCNA2 or CCNE1, 7 were previously analyzed by viral capture sequencing16 and 3 were analyzed by whole genome sequencing. For these 10 tumors, we were able to extract reads covering the full length of the inserted viral genome and to reconstruct the complete human-virus-human chimeric sequence.

Consequences of cyclin A2 alterations on protein structure

All tumors from the LICA-FR series harboring AAV2 or HBV insertions in CCNA2 were analyzed by WGS or viral capture16 to determine the precise boundaries of viral insertion breakpoints. RNA-seq reads were then aligned on the reconstructed chimeric sequence with TopHat258, and we used Cufflinks v2.2.166 to identify and quantify the different transcripts. We used ElemeNT67 to predict transcription initiation sites and Alamut Visual software (Interactive Biosoftware) to identify splicing signals on the chimeric DNA sequence. We used ATGpr68 to identify translation initiation sites on abnormal transcripts resulting from viral insertion or gene fusions.

Western blot analysis of cyclin A2 and cyclin E1 proteins

Cell protein extracts were prepared using hot Laemmli buffer (50 mM Tris, pH = 6.8, 2% SDS, 5% glycerol, 2 mM DTT, 2.5 mM EDTA, 2.5 mM EGTA, Protease inhibitor cocktail complete MINI EDTA-free (Roche Applied Science), 1× HALT Phosphatase inhibitor (Perbio), 2 mM Na3VO4 and 10 mM NaF). Protein concentration was assessed using the BCA Protein Assay Kit (Pierce). Western blot analyses were conducted using the following primary antibodies: CCNA2 N-ter (#211735, Abcam); CCNA2 C-ter (#32386, Abcam), CCNE1 (#33911, Abcam), and β-actin (#4967, Cell Signaling Technology) used as loading control. Proteins of interest were detected using an anti-rabbit IgG horseradish peroxidase–linked secondary antibody (#7074, Cell Signaling Technology) and the ECL Chemiluminescence Western Blotting Detection Kit (GE Healthcare), according to the provided protocol. Signal detection was performed using the ChemiDoc XRS system and the Image Lab software (Bio-Rad). All antibodies were used at 1:1000 dilution except secondary antibody, which was used at 1:2000.

Mutational and rearrangement signature analysis

We used the Palimpsest R package69 to extract mutational and rearrangement signatures from WGS data. For point mutations, we quantified the contribution of the 10 mutational signatures referenced on the COSMIC website (https://cancer.sanger.ac.uk/cosmic/signatures) and described as operative in liver cancers (signatures 1, 4, 5, 6, 12, 16, 17, 22, 23, 24)22 to each tumor genome. For structural rearrangements, we performed a de novo signature analysis across the 350 HCC genomes from the LICA-FR, TCGA and ICGC-JP datasets. We identified 6 rearrangement signatures that were very similar to the 6 signatures we previously obtained on a smaller dataset22, except that the two initially described deletion signatures were now merged into signature RS5, and that a new signature emerged (RS6, dominated by inversions < 10 kb). We used Palimpsest to quantify the contribution of each signature to each tumor genome and to estimate the probability of each structural rearrangement being due to each process.

Identification of rearrangement hotspots

We identified 8466 breakpoints attributed to signature RS1 (probability > 0.5) across the 350 HCC genomes from the LICA-FR, TCGA and ICGC-JP datasets. To account for the uneven distribution of rearrangements in the genome, we then modeled the background distribution of breakpoints considering various genomic features as described by Glodzik et al.27, with some modifications. In short, we divided the genome into 500 kb bins, and we characterized for each bin 17 genomic features likely to influence the density of rearrangements: replication timing in HepG2 cell line (ENCODE70), highly expressed (top 25%) and low-expressed (remaining 75%) genes in normal liver, average copy-number in the cohort, repetitive sequences (segmental duplications, ALU elements and other repeats), number of N bases in the reference genome, known fragile sites71, chromatin staining, DNAse hyper-sensitive sites and 6 histone marks (H3K4me1, H3K4me3, H3K9me3, H3K27me3, H3K36me3, H3K27ac) in adult liver (ROADMAP72). All features were normalized to a mean of 0 and standard deviation of 1 across the bins. The total number of RS1 breakpoints were counted for each bin, and we used negative binomial regression to model the distribution of breakpoints according to the 17 normalized features. The model was trained across 4993 bins after removing bins containing validated cancer genes from the Cancer Gene Census73 (https://cancer.sanger.ac.uk/census). For signature RS1, the most predictive features of a high breakpoint density were DNAse accessibility, H3K27 acetylation and early replication timing. We then used this model to estimate the expected number of breakpoints across 761 bins containing cancer genes, and we compared the number of observed breakpoints to the number of expected breakpoints using a one-sided binomial test. Finally, p-values were corrected for multiple testing using Benjamini-Hochberg procedure.

Chromatin state analysis

We used various genomic features to correlate with structural rearrangement density and to better understand the functional consequences of rearrangements. We used replication sequencing (Repli-seq) wavelet-smoothed signals downloaded generated by the ENCODE70 consortium for the liver cancer cell line HepG2 to define early and late-replicating regions. We used ChIP-seq data for various histone modifications (H3K4me1, H3K4me3, H3K9me3, H3K27me3, H3K36me3, H3K27ac) and chromatin states derived from these modifications in normal adult liver by the ROADMAP consortium72. Topologically associated domain (TAD) boundaries in human embryonic stem cells (H1) were provided by Tsirigos et al.74

Pan-cancer analysis of structural rearrangement signatures

Somatic structural rearrangements called by a uniform pipeline over 2,606 tumor genomes were downloaded from the ICGC PanCancer Analysis of Whole Genomes (PCAWG) project23,28,29. Using Palimpsest69, we identified 9 rearrangement signatures in this data set, including one (RS1-pancan) very similar to the RS1 signature identified in CCN-HCC, and we quantified the contribution of each signature to each tumor genome. In each cancer type, we tested if the presence of ≥ 50 rearrangements attributed to signature RS1-pancan was associated with the presence of rearrangement breakpoints < 80 kb from CCNA2 or CCNE1 gene using Fisher’s exact test. We analyzed two additional series of breast (n = 524)30 and ovarian (n = 80)75 cancer genomes to correlate the amount of RS1-pancan events with CCNE1 amplifications and BRCA1 alterations.

Clinical associations

We tested the association of CCN-HCC in the LICA-FR cohort with gender, age, etiology, liver fibrosis, Edmonson grade, and vascular invasion using Wilcoxon rank sum test for continuous variables, Fisher’s exact test for binary variables and Chi square test for trend for categorical variables. We used log-rank test and Kaplan–Meier method to compare overall survival between CCN-HCC and others, considering only HCC with curative resection (R0) and excluding patients who died within 3 months after surgery.

Computing codes

The functions used to perform the signatures analysis and associated figures are available as an open-source R package, Palimpsest, available on Github: https://github.com/FunGeST/Palimpsest.


ICGC data portal, https://dcc.icgc.org/; COSMIC database, https://cancer.sanger.ac.uk/cosmic; ENCODE project, https://www.encodeproject.org; GENCODE v19, http://www.gencodegenes.org/releases/19.html; ROADMAP project, http://www.roadmapepigenomics.org; NCI GDC data portal, https://portal.gdc.cancer.gov.

Data availability

The sequencing data reported in this paper have been deposited to the EGA (European Genome-phenome Archive) database (RNA-seq accession [EGAS00001002879]; WES accessions [EGAS00001000217], [EGAS00001001002] and [EGAS00001003063]; WGS accessions [EGAS00001002408], [EGAS00001000706] and [EGAS00001002888]) and the Inter- national Cancer Genome Consortium (ICGC) data portal (http://dcc.icgc.org/; release 27, April 2018).

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).

  2. 2.

    Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. New Engl. J. Med. 359, 378–390 (2008).

  3. 3.

    Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).

  4. 4.

    Llovet, J. M. & Hernandez-Gea, V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072–2079 (2014).

  5. 5.

    Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2, 16018 (2016).

  6. 6.

    Nault, J. C. et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60, 1983–1992 (2014).

  7. 7.

    Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694–698 (2012).

  8. 8.

    Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760–764 (2012).

  9. 9.

    Ahn, S.-M. et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972–1982 (2014).

  10. 10.

    Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505–511 (2015).

  11. 11.

    Fujimoto, A. et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500–509 (2016).

  12. 12.

    Zucman-Rossi, J., Villanueva, A., Nault, J.-C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226–1239.e4 (2015).

  13. 13.

    Wang, J., Chenivesse, X., Henglein, B. & Bréchot, C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343, 555–557 (1990).

  14. 14.

    Sung, W.-K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765–769 (2012).

  15. 15.

    Ding, D. et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet. 8, e1003065 (2012).

  16. 16.

    Nault, J.-C. et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 47, 1187–1193 (2015).

  17. 17.

    Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu & Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327–1341.e23 (2017).

  18. 18.

    Geley, S. et al. Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J. Cell. Biol. 153, 137–148 (2001).

  19. 19.

    Fung, T. K., Yam, C. H. & Poon, R. Y. C. The N-terminal regulatory domain of cyclin A contains redundant ubiquitination targeting sequences and acceptor sites. Cell Cycle 4, 1411–1420 (2005).

  20. 20.

    Sage, J., Miller, A. L., Pérez-Mancera, P. A., Wysocki, J. M. & Jacks, T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424, 223–228 (2003).

  21. 21.

    Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor suppressive metabolic state. Cell 149, 49–62 (2012).

  22. 22.

    Letouzé, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat. Commun. 8, 1315 (2017).

  23. 23.

    Li, Y. et al. Patterns of structural variation in human cancer. Preprint at https://www.biorxiv.org/content/early/2017/08/27/181339, https://doi.org/10.1101/181339 (2017).

  24. 24.

    Lee, J. A., Carvalho, C. M. B. & Lupski, J. R. A. DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell 131, 1235–1247 (2007).

  25. 25.

    Hastings, P. J., Ira, G. & Lupski, J. R. A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genet. 5, e1000327 (2009).

  26. 26.

    Carvalho, C. M. B. et al. Inverted genomic segments and complex triplication rearrangements are mediated by inverted repeats in the human genome. Nat. Genet. 43, 1074–1081 (2011).

  27. 27.

    Glodzik, D. et al. A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nat. Genet. 49, 341–348 (2017).

  28. 28.

    Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O. & Stein, L. D. Pan-cancer analysis of whole genomes. Preprint at https://www.biorxiv.org/content/early/2017/07/12/162784, https://doi.org/10.1101/162784 (2017).

  29. 29.

    Wala, J. A. et al. Selective and mechanistic sources of recurrent rearrangements across the cancer genome. Preprint at https://www.biorxiv.org/content/early/2017/09/14/187609, https://doi.org/10.1101/187609 (2017).

  30. 30.

    Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).

  31. 31.

    Waszak, S. M. et al. Germline determinants of the somatic mutation landscape in 2,642 cancer genomes. Preprint at https://www.biorxiv.org/content/early/2017/11/01/208330, https://doi.org/10.1101/208330 (2017).

  32. 32.

    Macheret, M. & Halazonetis, T. D. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature 555, 112–116 (2018).

  33. 33.

    Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106–116 (2012).

  34. 34.

    Pathania, S. et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat. Commun. 5, 5496 (2014).

  35. 35.

    Willis, N. A. et al. Mechanism of tandem duplication formation in BRCA1-mutant cells. Nature 551, 590–595 (2017).

  36. 36.

    Forment, J. V. & O’Connor, M. J. Targeting the replication stress response in cancer. Pharmacol. Ther. https://doi.org/10.1016/j.pharmthera.2018.03.005 (2018).

  37. 37.

    Menghi, F. et al. The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proc. Natl Acad. Sci. USA 113, E2373–E2382 (2016).

  38. 38.

    Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158 (2017).

  39. 39.

    O’Connor, M. J. Targeting the DNA damage response in cancer. Mol. Cell 60, 547–560 (2015).

  40. 40.

    Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721–727 (2011).

  41. 41.

    Honeyman, J. N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010–1014 (2014).

  42. 42.

    Gao, Q. et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 23, 227–238.e3 (2018).

  43. 43.

    Conner, E. A. et al. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 19, 5054–5062 (2000).

  44. 44.

    Ladu, S. et al. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 135, 1322–1332 (2008).

  45. 45.

    Kramara, J., Osia, B. & Malkova, A. Break-induced replication: the where, the why, and the how. Trends Genet. 34, 518–531 (2018).

  46. 46.

    Costantino, L. et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 343, 88–91 (2014).

  47. 47.

    Smith, C. E., Llorente, B. & Symington, L. S. Template switching during break-induced replication. Nature 447, 102–105 (2007).

  48. 48.

    Saini, N. et al. Migrating bubble during break-induced replication drives conservative DNA synthesis. Nature 502, 389–392 (2013).

  49. 49.

    Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

  50. 50.

    Etemadmoghadam, D. et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl Acad. Sci. USA 110, 19489–19494 (2013).

  51. 51.

    Sanchez-Vega, F. et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173, 321–337.e10 (2018).

  52. 52.

    Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

  53. 53.

    McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).

  54. 54.

    DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).

  55. 55.

    Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220–1222 (2016).

  56. 56.

    Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).

  57. 57.

    Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004).

  58. 58.

    Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).

  59. 59.

    Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).

  60. 60.

    Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

  61. 61.

    van der Maaten, L. & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).

  62. 62.

    Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).

  63. 63.

    Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

  64. 64.

    Li, H. et al. The sequence alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

  65. 65.

    Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).

  66. 66.

    Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).

  67. 67.

    Sloutskin, A. et al. ElemeNT: a computational tool for detecting core promoter elements. Transcription 6, 41–50 (2015).

  68. 68.

    Nishikawa, T., Ota, T. & Isogai, T. Prediction whether a human cDNA sequence contains initiation codon by combining statistical information and similarity with protein sequences. Bioinformatics 16, 960–967 (2000).

  69. 69.

    Shinde, J. et al. Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics. https://doi.org/10.1093/bioinformatics/bty388 (2018).

  70. 70.

    ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).

  71. 71.

    Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893–898 (2010).

  72. 72.

    Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).

  73. 73.

    Futreal, P. A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).

  74. 74.

    Gong, Y. et al. Stratification of TAD boundaries reveals preferential insulation of super-enhancers by strong boundaries. Nat. Commun. 9, 542 (2018).

  75. 75.

    Patch, A.-M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).

Download references


We thank Hidewaki Nakagawa for fruitful discussions and providing TERT promoter mutation data for the ICGC-JP series. We thank Rameen Beroukhim and Joachim Weischenfeldt for helping us access ICGC structural variant tables, and Aristotelis Tsirigos for providing topologically associated domain boundaries. We thank Tatiana Popova and Céline Vallot for critical discussion of the results. We thank the principal investigators of the liver cancer TCGA (Lewis Roberts, David Wheeler) and ICGC-JP (Tatsuhiro Shibata, Hidewaki Nakagawa) projects, and the ICGC consortium as a whole for providing the high quality data sets used in this study. We thank all the clinician surgeons and pathologists who have participated to this work: Jean Saric, Christophe Laurent, Laurence Chiche, Brigitte Le Bail, Claire Castain (CHU Bordeaux), Alexis Laurent, Daniel Cherqui, Daniel Azoulay (CHU Henri Mondor, Créteil, APHP), Marianne Ziol, Nathalie Ganne-Carrié and Pierre Nahon (Jean Verdier Hospital, Bondy, APHP). We also thank the Réseau national CRB Foie (BB-0033-0085), the tumor banks of CHU Bordeaux (BB-0033-00036), Jean Verdier Hospital (APHP) and CHU Henri Mondor (APHP) for contributing to the tissue collection. This work was supported by INCa within the ICGC project, MUTHEC project (INCa translationnel PRTK2014), France Génomique, Cancéropole Ile de France (ExhauTrans project), ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Santé, National Alliance for Life Sciences & Health) within the framework of the Cancer Plan (“HTE program-HetColi network” and “Cancer et environnement program”), BPI France (ICE project), ANRS and the French Liver Biobanks network – INCa, BB-0033-00085, Hepatobio bank. The group is supported by the Ligue Nationale Contre le Cancer (Equipe Labellisée), Labex OncoImmunology (investissement d’avenir), Coup d’Elan de la Fondation Bettencourt-Shueller, the SIRIC CARPEM and Fondation Mérieux. QB and LM are supported by a fellowship from the HOB doctoral school and the ministry of Education and Research, TLB is supported by an “Attractivite IDEX” fellowship from IUH and CP is supported by a doctoral fellowship funded by ANRS.

Author information

Author notes

  1. These authors contributed equally: Léa Meunier, Camille Peneau.

  2. These authors jointly supervised this work: Jessica Zucman-Rossi, Eric Letouzé.


  1. INSERM, UMR-1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue Contre le Cancer, Institut Universitaire d’Hématologie, Paris, 75010, France

    • Quentin Bayard
    • , Léa Meunier
    • , Camille Peneau
    • , Jayendra Shinde
    • , Jean-Charles Nault
    • , Iadh Mami
    • , Gabrielle Couchy
    • , Tiziana La Bella
    • , Olivier Seror
    • , Sandrine Imbeaud
    • , Jessica Zucman-Rossi
    •  & Eric Letouzé
  2. Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Faculté de Médecine, Paris, 75006, France

    • Quentin Bayard
    • , Léa Meunier
    • , Camille Peneau
    • , Jayendra Shinde
    • , Jean-Charles Nault
    • , Iadh Mami
    • , Gabrielle Couchy
    • , Tiziana La Bella
    • , Sandrine Imbeaud
    • , Jessica Zucman-Rossi
    •  & Eric Letouzé
  3. Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche Santé, Médecine, Biologie Humaine, Bobigny, 93017, France

    • Quentin Bayard
    • , Léa Meunier
    • , Camille Peneau
    • , Jayendra Shinde
    • , Jean-Charles Nault
    • , Iadh Mami
    • , Gabrielle Couchy
    • , Tiziana La Bella
    • , Sandrine Imbeaud
    • , Jessica Zucman-Rossi
    •  & Eric Letouzé
  4. Université Paris Diderot, Sorbonne Paris Cité, Paris, 75013, France

    • Quentin Bayard
    • , Léa Meunier
    • , Camille Peneau
    • , Jayendra Shinde
    • , Jean-Charles Nault
    • , Iadh Mami
    • , Gabrielle Couchy
    • , Tiziana La Bella
    • , Sandrine Imbeaud
    • , Jessica Zucman-Rossi
    •  & Eric Letouzé
  5. Laboratory for Bioinformatics, Fondation Jean Dausset – CEPH, Paris, 75010, France

    • Victor Renault
    • , Emmanuel Tubacher
    •  & Jean-François Deleuze
  6. Liver unit, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, APHP, Bondy, 93140, France

    • Jean-Charles Nault
  7. Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d’Universités et Etablissements Sorbonne Paris Cité, Bobigny, 93017, France

    • Jean-Charles Nault
  8. Inserm, U955, Team 18, Université Paris-Est Créteil, Faculté de Médecine, Créteil, 94010, France

    • Giuliana Amaddeo
    •  & Julien Calderaro
  9. Assistance Publique-Hôpitaux de Paris, Service d’Hépatologie, CHU Henri Mondor, Créteil, 94010, France

    • Giuliana Amaddeo
  10. Centre National de Recherche en Génomique Humaine, CEA, Evry, 91000, France

    • Delphine Bacq
    • , Vincent Meyer
    •  & Jean-François Deleuze
  11. Service Hépato-Gastroentérologie et Oncologie Digestive, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 33076, France

    • Audrey Debaillon-Vesque
    •  & Jean-Frédéric Blanc
  12. Université Bordeaux, Bordeaux Research in Translational Oncology, Bordeaux, 33076, France

    • Paulette Bioulac-Sage
    •  & Jean-Frédéric Blanc
  13. Service de Pathologie, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 33000, France

    • Paulette Bioulac-Sage
  14. Radiology Department, Jean Verdier Hospital, Hôpitaux Universitaires Paris-Seine-Saint-Denis, APHP, Bondy, 93140, France

    • Olivier Seror
  15. Assistance Publique-Hôpitaux de Paris, Département de Pathologie, Hôpital Henri Mondor, Créteil, 94010, France

    • Julien Calderaro
  16. Assistance Publique-Hôpitaux de Paris, Hopital Européen Georges Pompidou, 75015, Paris, France

    • Jessica Zucman-Rossi


  1. Search for Quentin Bayard in:

  2. Search for Léa Meunier in:

  3. Search for Camille Peneau in:

  4. Search for Victor Renault in:

  5. Search for Jayendra Shinde in:

  6. Search for Jean-Charles Nault in:

  7. Search for Iadh Mami in:

  8. Search for Gabrielle Couchy in:

  9. Search for Giuliana Amaddeo in:

  10. Search for Emmanuel Tubacher in:

  11. Search for Delphine Bacq in:

  12. Search for Vincent Meyer in:

  13. Search for Tiziana La Bella in:

  14. Search for Audrey Debaillon-Vesque in:

  15. Search for Paulette Bioulac-Sage in:

  16. Search for Olivier Seror in:

  17. Search for Jean-Frédéric Blanc in:

  18. Search for Julien Calderaro in:

  19. Search for Jean-François Deleuze in:

  20. Search for Sandrine Imbeaud in:

  21. Search for Jessica Zucman-Rossi in:

  22. Search for Eric Letouzé in:


J.Z-R. and E.L. conceived and directed the research. Q.B., L.M., C.P., S.I., J.Z-R., and E.L. designed the study and wrote the manuscript. C.P., I.M., G.C., and T.L-B. performed the experiments. Q.B., L.M., C.P., I.M., T.L-B., S.I., J.Z-R., and E.L. analyzed and interpreted the data. D.B., V.M., and J-F.D. generated whole-genome sequencing data. Q.B., L.M., C.P., V.R., J.S., E.T., D.B., V.M. S.I., and E.L. performed bioinformatics and statistical analysis. J-C.N., G.A., A.D-V, P.B-S., O.S., J-F.B., and J.C. provided essential biological resources and collected clinical data. All authors approved the final manuscript and contributed to critical revisions to its intellectual context.

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Jessica Zucman-Rossi or Eric Letouzé.

Electronic supplementary material

About this article

Publication history







By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.